Abstract 1001P
Background
Patients with cancer have reported an unmet need regarding education of all treatment options available to them and their impact on survival and quality of life (QoL). This is especially true for patients with HCC in a time of new treatment options like immunotherapy. This study qualitatively explored patients’ prioritized treatment goals and cross-referenced them to those of treating physicians.
Methods
Qualitative semi-structured interviews were conducted with patients with HCC and physicians who managed their care in the US, Germany, France, and Japan. Interviews were conducted with physicians (n=12, n=3 per country) and patients (n=51 [10-15/country]) with early (n=20), intermediate (n=15), or advanced (n=16) HCC. Qualitative data were analyzed using directed content analysis techniques and quantitative demographic data were descriptively summarized.
Results
Patients shared a wide range of physical and emotional impacts when describing their HCC journey including fatigue, nausea, appetite loss, diarrhea, and pain. Patients described their role in treatment decision-making as passive but most felt well-informed and involved. Patients described that overall survival (OS) and QoL were most important, in addition to avoiding relapse and disease progression, and were generally similar across the three stages of HCC. Patients did not refer to side effects/safety of treatment as specific treatment considerations but prioritized their overall QoL as an important factor in their treatment decision-making. Physicians identified OS, progression-free survival, and safety/tolerability as important treatment goals and reported that they discussed realistic goals with patients. Treatment pathways and physician decision-making were mainly based on country-specific guidelines and multidisciplinary tumor board recommendations.
Conclusions
Extending survival and improving QoL were important treatment goals for patients. Discussing the benefits and risks of available treatment options with patients is important to ensure they have the opportunity to achieve outcomes aligned to their treatment goals.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
AstraZeneca.
Funding
AstraZeneca.
Disclosure
M. Wörns: Financial Interests, Personal, Other, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: AbbVie, AstraZeneca, Bayer, Boston Scientific, Bristol Myers Squibb, Celgene, Dr. Falk Pharma, Gilead Sciences, Incyte, Ipsen, Janssen-Cilag, MSD Sharp & Dohme, MYR Pharma-ceuticals, Roche Pharma, SOBI; Financial Interests, Personal, Other, Support for attending meetings and/or travel: AbbVie, Bayer, Bristol Myers Squibb, Gilead Sciences, Ipsen, Lilly, Roche Pharma; Financial Interests, Personal, Other, Participation on a Data Safety Monitoring Board or Advisory Board: AbbVie, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Gilead Sciences, Ipsen, Incyte, MSD Sharp & Dohme, MYR Pharmaceuticals, Nordic Pharma, Roche Pharma, SOBI; Non-Financial Interests, Personal, Other, Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten: S3-Leitlinie Diagnostik und Therapie biliärer Karzinome, S3-Leitlinie Diagnostik und Therapie des Hepatozellulären Karzinoms. D. Burns: Financial Interests, Personal, Full or part-time Employment: Clarivate; Financial Interests, Personal, Stocks/Shares, Restricted Stock Units (RSUs) as employee.: Clarivate. J. Sah: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca. H. Makin: Financial Interests, Personal, Stocks/Shares, Restricted Stock Units (RSUs) as employee.: Clarivate; Financial Interests, Personal, Full or part-time Employment: Clarivate. G. Al-Jassar: Financial Interests, Personal, Full or part-time Employment: Cla. L. Turner: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca. M. Paskow: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca.
Resources from the same session
967P - The effect of prognosis value of EZH2 (Enhancer Of Zeste Homologue) staining in hepatocellular cancer
Presenter: Mehmet Kidi
Session: Poster session 18
968P - High sensitivity routine blood based detection of HCC: An AI model from 220k patients
Presenter: Kin Nam Kwok
Session: Poster session 18
969P - Establishing a novel routine blood component signature for Hepatocellular Carcinoma (HCC) screening with big clinical data
Presenter: Ka Man Cheung
Session: Poster session 18
970P - Real-world multi-center study of systemic treatment after first-line atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in Asia-Pacific countries
Presenter: Choong-kun Lee
Session: Poster session 18
971P - Effect of preoperative frailty on surgical outcomes following hepatic resection for elderly patients with hepatocellular carcinoma: A multicenter retrospective cohort study from China
Presenter: Zhongqi Fan
Session: Poster session 18
972P - Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in advanced hepatocellular carcinoma
Presenter: Mara Persano
Session: Poster session 18
973P - Clinicopathologic and treatment outcome data in 165 fibrolamellar carcinoma patients
Presenter: Sunyoung Lee
Session: Poster session 18
974P - The barthel index predicts surgical textbook outcomes following hepatectomy for elderly patients with hepatocellular carcinoma: A multicenter cohort study from China
Presenter: Guoyue Lv
Session: Poster session 18
975P - The clinical impact of urinary protein creatinine ratio and AFP at six weeks in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Presenter: Kaoru Tsuchiya
Session: Poster session 18
976P - Overall survival in advanced hepatocellular carcinoma treated with concomitant systemic therapy and stereotactic radiation therapy or systemic therapy alone
Presenter: Alexander Piening
Session: Poster session 18